SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining significant momentum and trending as investors react to the completed acquisition of Astria Therapeutics and prepare for upcoming data presentations at the AAAAI annual meeting. The community is actively discussing the stock's potential valuation floor, ongoing high short interest, and the disruptive potential of the navenibart pipeline program to trigger a reversal in the long-term price trend.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing heightened volatility and intense community debate as traders weigh the potential for a breakout against ongoing frustration over price stagnation. Sentiment remains sharply divided between investors betting on a long-term utility-driven surge and critics who view the asset's current performance as a manipulated, speculative trap.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is currently a focal point of intense community debate, with bulls tracking potential supply reduction rumors and long-term accumulation strategies, while bears express skepticism regarding its historical performance and long-term viability. The conversation remains highly polarized, centered on whether the asset will experience a renewed rally or continue to struggle within the broader meme coin market.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is seeing significant investor attention driven by positive clinical data updates for its Varsetatug Masetecan (CX-2051) candidate in colorectal cancer, despite some community skepticism regarding recent financial results. Traders are actively monitoring the stock for potential momentum as the company progresses toward upcoming clinical milestones and expansion trials, with many discussions focusing on its long-term potential as a buyout candidate.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing increased momentum as investors track the upcoming May 31 PDUFA date for its ADHD treatment, CTx-1301, while closely monitoring for news on a potential U.S. patent allowance. The community is heavily focused on the company's low share float and recent strategic financing, leading to strong sentiment regarding its potential for volatility and significant upside as commercialization milestones approach.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery ($MERY) is trending as a leading native meme coin on the Cronos blockchain, drawing investor attention due to its strong correlation with $CRO and community enthusiasm regarding its perceived 'rug-proof' nature driven by exchange-level ownership. Traders are actively comparing its growth potential to historical meme coin breakouts, with many interpreting current activity as a setup for a sustained bull run.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging following a massive five-year AI infrastructure agreement with Meta valued at up to $27 billion, further cementing its position as a primary AI hyperscaler. The community is actively debating the stock's long-term valuation against its recent backlog expansion and price action, with many investors highlighting the rare 'three-counterparty validation' from Microsoft, Meta, and NVIDIA as a key driver of institutional confidence.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently under significant pressure following an earnings report that missed revenue expectations and highlighted ongoing bottom-line struggles, fueling intense debate between retail investors who are buying the dip and skeptics concerned about high debt levels and management's performance. The community remains heavily focused on the status of a potential strategic partnership with POSCO and the impact of steel tariffs on the companys long-term recovery.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and bullish sentiment as investors speculate on potential news or partnership announcements during the upcoming OFC conference. The community is actively debating the company's competitive position in the AI infrastructure and optical interconnect sector, with many focused on the potential for the firm's interposer platform to capture share in the data center market.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is seeing high volatility as investors closely monitor for the anticipated announcement of a major hyperscaler tenant for its data center project. While social media sentiment remains divided between hopeful bulls expecting significant upside upon a contract filing and vocal skeptics concerned about project timelines and recent share registration activity, the community is actively tracking industrial progress and energy infrastructure developments as key indicators for a potential breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Breakthroughs and Capital Moves Drive a Busy Market Week

A wave of biotech developments, strategic financings, and emerging-technology announcements shaped market narratives this week, highlighting how innovation across biopharma, AI-driven automation, energy technology, and crypto finance continues to drive investor attention. $CTMX, $NVDA, $HCWB, $KBLB, $CYN, $BMNR, $CLIK, $CIIT, $AIRS, $DFLI

CytomX Therapeutics Q4 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) outlined updated Phase 1 dose expansion results for its EpCAM-targeting Probody antibody-drug conjugate (ADC) varsetatug masetecan (Varseta-M, Varseta ) during a...

CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -175.00% and -90.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>The trial, started in April 2024, involved 93 advanced late-line metastatic colorectal cancer patients (CRC).</li><li>&nbsp;Across all dose levels, 88% of patients showed signs of disease control.</li><li>The company plans to engage with the FDA later this year on a potential registrational trial for the therapy.</li></ul>CytomX Therapeutics, Inc. (CTMX) on Monday announced encouraging early results from its Phase 1 expansion study of varsetatug masetecan (Varseta-M) in patients with late-line metastatic colorectal cancer (CRC).&nbsp;The data, as of January 16, indicated the antibody-drug conjugate is showing meaningful response rates across higher dose levels.&nbsp;Following the results,&nbsp;<a href="https://stocktwits.com/symbol/CTMX">CytomX Therapeutics stock</a> traded over 54% in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Promising Early Efficacy Signals In Phase 1 Study&nbsp;</h2>The CTMX-2051-101 trial, which began in April 2024, included 93 patients with advanced colorectal cancer who had already received multiple treatments. Out of these 56 could be assessed for how well the treatment worked.Participants received increasing doses of 7.2 mg/kg, 8.6 mg/kg, or 10 mg/kg every three weeks. Treatment responses improved as the dose increased. 6% of patients responded at 7.2 mg/kg, 20% at 8.6 mg/kg, and 32% at 10 mg/kg. Overall, 88% of patients across all doses experienced some level of disease control.CytomX plans to present additional Phase 1 data at medical meetings later in 2026. The company will engage with the FDA mid-year to discuss registrational trial design for Varseta-M monotherapy in advanced CRC.<h2 class="st-heading-2">Financial Performance: Revenue Declines As Collaboration Milestones End</h2>Revenue fell 44.8% year-on-year (YoY) to $76.2 million from $138.1 million in 2025, largely due to the completion of Bristol Myers Squibb collaboration obligations and slower recognition from Moderna, Astellas, and Regeneron partnerships.&nbsp;Operating expenses dropped 12.8% YoY to $98.6 million, with R&amp;D costs decreasing to $68.7 million following restructuring and strategic pipeline focus. CytomX closed 2025 with $137.1 million in cash, cash equivalents, and investments, providing a runway into Q2 2027.&nbsp;CTMX stock has gained over 642% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-consolidating-ai-empire-signaling-the-next-phase-of-monetization-push/cZ32wVrRIf0">Alibaba Is Reportedly Consolidating Its AI Empire – Signaling The Next Phase Of Monetization Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CytomX Therapeutics logo is displayed on the screen of a tablet.

Why CTMX Stock Is Soaring 54% Pre-Market Today? 

CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.

Equity

CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.


CytomX Therapeutics (NASDAQ:CTMX) Posts Earnings Results, Misses Expectations By $0.14 EPS

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts' consensus...

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss of 9 cents per share. Stock fell 3.9% on Friday.read more...

CytomX Therapeutics, Inc. $CTMX Shares Bought by Baker BROS. Advisors LP

Baker BROS. Advisors LP raised its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 22.0% in the third quarter, according to its most recent 13F filing with the SEC. The...

CytomX Therapeutics (NASDAQ:CTMX) Receives "Buy" Rating from Guggenheim

Guggenheim reiterated a "buy" rating and set a $10.00 price objective on shares of CytomX Therapeutics in a research note on Monday...

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +14.11% and +56.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics Target of Unusually High Options Trading (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw unusually large options trading activity on Wednesday. Traders purchased 20,170 call options on the company. This is an increase of...

$CTMX Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.22 down -195.65% YoY
• Reported revenue of $0.66M down -98.26% YoY
• CytomX expects existing capital to fund operations into Q2 2027 and aims to align with the FDA in 2026 on a potential registrational study for Varseta-M monotherapy in advanced late-line CRC.

Stocktwits

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.22 down -195.65% YoY
• Reported revenue of $0.66M down -98.26% YoY
• CytomX expects existing capital to fund operations into Q2 2027 and aims to align with the FDA in 2026 on a potential registrational study for Varseta-M monotherapy in advanced late-line CRC.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Traders are reacting to highly positive Phase 1 expansion data for Varsetatug Masetecan in late-line colorectal cancer, with confirmed ORR reaching 32% and median PFS of 7.1 months.

Intense debate among traders as short sellers face mounting pressure and losses amid the stock's significant surge, sparking discussions of potential squeezes.

Significant concern over the recently filed $250M mixed securities shelf, with many users fearing imminent dilution and its impact on stock value despite positive drug data.

Despite other positive news, the company reported a GAAP EPS of -$0.22 and a 98% revenue drop, leading to debate among traders about the stock's true valuation.

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest CTMX News

CTMXCytomX Therapeutics Inc